Neuroimaging in Parkinson disease: from research setting to clinical practice

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature Reviews Neurology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrneurol.2014.205PMID 25385334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease

  2015cited by this paper
• Serotonin in Parkinson's disease.

  2015cited by this paper
• Dopamine receptor mapping with PET imaging in Parkinson’s disease

  2014cited by this paper
• Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head‐to‐head comparison

  2014cited by this paper
• Dyskinesias in Parkinson's disease: views from positron emission tomography studies

  2014cited by this paper
• Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

  2014cited by this paper
• Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.

  2014cited by this paper
• Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone

  2014cited by this paper
• Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

  2014cited by this paper
• Diffusion tensor imaging in parkinsonian syndromes

  2013cited by this paper
• Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

  2013cited by this paper
• Validation of parkinsonian disease‐related metabolic brain patterns

  2013cited by this paper
• MR-Based PET attenuation correction for PET/MR imaging.

  2013cited by this paper
• Attenuation Correction Synthesis for Hybrid PET-MR Scanners

  2013cited by this paper
• Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD

  2013cited by this paper
• Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease.

  2013cited by this paper
• Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

  2013cited by this paper
• Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.

  2013cited by this paper
• Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients

  2013cited by this paper
• Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach

  2013cited by this paper
• Self-gated Radial MRI for Respiratory Motion Compensation on Hybrid PET/MR Systems

  2013cited by this paper
• Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease.

  2013cited by this paper
• Differential Diagnosis Tool for Parkinsonian Syndrome Using Multiple Structural Brain Measures

  2013cited by this paper
• Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease

  2012cited by this paper
• Impulse control disorders in Parkinson's disease.

  2012cited by this paper
• Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

  2012cited by this paper
• The economic cost of brain disorders in Europe

  2012cited by this paper
• Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia

  2012cited by this paper
• MRI for attenuation correction in PET: methods and challenges

  2012cited by this paper
• PET/MRI for Neurologic Applications

  2012cited by this paper
• The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.

  2012cited by this paper
• Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait

  2012cited by this paper
• Progression of cortical thinning in early Parkinson's disease

  2012cited by this paper
• Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.

  2012cited by this paper
• In vivo imaging of the integration and function of nigral grafts in clinical trials.

  2012cited by this paper
• Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI

  2012cited by this paper
• The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study

  2012cited by this paper
• The relationship between cerebral vascular disease and parkinsonism: The VADO study.

  2012cited by this paper
• Clinical application of stem cell therapy in Parkinson's disease

  2012cited by this paper
• [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism

  2012cited by this paper
• Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease

  2012cited by this paper
• Pattern of brain tissue loss associated with freezing of gait in Parkinson disease

  2012cited by this paper
• Resting state functional connectivity of the striatum in Parkinson's disease.

  2012cited by this paper
• Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson’s Patients Treated with Dopamine Grafts

  2012cited by this paper
• Functional Neural Transplantation III

  2012cited by this paper
• Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach

  2011cited by this paper
• Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients

  2011cited by this paper
• Serotonergic mediated body mass index changes in Parkinson's disease.

  2011cited by this paper
• Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study

  2011cited by this paper
• Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

  2011cited by this paper
• Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

  2011cited by this paper
• Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.

  2011cited by this paper
• Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio

  2011cited by this paper
• Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

  2011cited by this paper
• Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

  2011cited by this paper
• The aging brain and neurodegenerative diseases.

  2011cited by this paper
• Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease

  2011cited by this paper
• In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

  2011cited by this paper
• Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

  2010cited by this paper
• Parkinson's disease symptoms: The patient's perspective

  2010cited by this paper
• Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

  2010cited by this paper
• Serotonin 2A receptors and visual hallucinations in Parkinson disease.

  2010cited by this paper
• Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD

  2010cited by this paper
• Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study.

  2010cited by this paper
• Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.

  2010cited by this paper
• Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

  2010cited by this paper
• Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.

  2010cited by this paper
• Neurology: A Queen Square Textbook

  2009cited by this paper
• Degenerative changes were common in brain magnetic resonance imaging in patients with newly diagnosed Parkinson’s disease in a population-based cohort

  2009cited by this paper
• Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study.

  2009cited by this paper
• Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

  2009cited by this paper
• History of falls in Parkinson disease is associated with reduced cholinergic activity

  2009cited by this paper
• Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.

  2009cited by this paper
• A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

  2009cited by this paper
• Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management

  2009cited by this paper
• PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

  2009cited by this paper
• Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

  2008cited by this paper
• Imaging amyloid deposition in Lewy body diseases

  2008cited by this paper
• Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

  2008cited by this paper
• The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

  2008cited by this paper
• The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study.

  2008cited by this paper
• [11C]PIB binding in Parkinson's disease dementia

  2008cited by this paper
• Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

  2008cited by this paper
• Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB

  2008cited by this paper
• Simultaneous MR/PET imaging of the human brain: feasibility study.

  2008cited by this paper
• Imaging β-amyloid burden in aging and dementia

  2007cited by this paper
• Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

  2007cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

  2007cited by this paper
• Imaging beta-amyloid burden in aging and dementia.

  2007cited by this paper
• [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease

  2007cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

  2006cited by this paper
• Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease

  2006cited by this paper
• Clinical correlates of levodopa-induced dopamine release in Parkinson disease

  2006cited by this paper
• A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

  2006cited by this paper
• Compulsive drug use linked to sensitized ventral striatal dopamine transmission

  2006cited by this paper

• The infectious potential of protein misfolding: insights from cross-over studies of prion diseases and common neurodegenerative disorders.

  2025cites this paper
• Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review

  2025cites this paper
• Quantitative multi-metabolite imaging of Parkinson’s disease using AI boosted molecular MRI

  2025influential citation
• Combining Dopamine Transporter and Amyloid PET Tracer: A Preclinical Study on Dual-Target Imaging

  2025cites this paper
• The Effects of Table Tennis on Motor Function and Cognitive Performance in Parkinson’s Disease

  2025cites this paper
• Cross-modality PET image synthesis for Parkinson’s Disease diagnosis: a leap from [18F]FDG to [11C]CFT

  2025cites this paper
• Parkinson’s Disease Detection via Bilateral Gait Camera Sensor Fusion Using CMSA-Net and Implementation on Portable Device

  2025cites this paper
• Oligodendroglia vulnerability in the human dorsal striatum in Parkinson’s disease

  2025cites this paper
• Semiautomatic Quantification of 99mTc‐TRODAT‐1 SPECT Images in Patients With Idiopathic Parkinson's Disease

  2025cites this paper
• Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study

  2025cites this paper
• Exploring Protein Misfolding and Aggregate Pathology in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Interventions

  2025influential citation
• Beyond Clathrin: Decoding the Mechanism of Ultrafast Endocytosis.

  2025cites this paper
• Mapping striatal functional gradients and associated gene expression in Parkinson’s disease with continuous cognitive impairment

  2025cites this paper
• Molecular connectivity studies in neurotransmission: a scoping review

  2025cites this paper
• The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism

  2025cites this paper
• Detection and Stage Classification of Parkinson’s Disease with LSTM Networks Leveraging Eye Movement Data

  2025cites this paper
• Current trends in blood biomarkers detection and neuroimaging for Parkinson's disease.

  2025cites this paper
• Investigation on Enhanced Detection of Parkinson's Disease in Brain Imaging Using Ensemble Learning Approaches

  2025cites this paper
• Detection of Parkinson's disease using nocturnal breathing signals based on multifractal detrended fluctuation analysis.

  2024cites this paper
• In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development.

  2024cites this paper
• Shannon Wavelet Entropy-based Machine Learning Applications in Parkinson’s Disease Diagnosis with Videonystagmography

  2024cites this paper
• Neuronal SLC39A8 deficiency impairs cerebellar development by altering manganese homeostasis

  2024cites this paper
• Ratiometric Fluorescent Probe Promotes Trans-differentiation of Human Mesenchymal Stem Cells to Neurons.

  2024cites this paper
• Multiparametric quantitative MRI uncovers putamen microstructural changes in Parkinson’s disease

  2024cites this paper
• Synthetic data in generalizable, learning-based neuroimaging

  2024cites this paper
• Advancements in ultrasonography and MRI for enhanced diagnosis of Parkinson's disease: An updated review

  2024cites this paper
• Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis

  2024cites this paper
• Differential diagnosis value of sympathetic skin response and cutaneous silent period on early-stage multiple system atrophy and Parkinson disease.

  2024cites this paper
• Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson’s disease patients

  2024cites this paper
• Distinctive clinical and imaging trajectories in SWEDD and Parkinson’s disease patients

  2024cites this paper
• Thai national guideline for nuclear medicine investigation in movement disorders: Nuclear medicine society of Thailand, the neurological society of Thailand, and Thai medical physicist society collaboration

  2024cites this paper
• Hypo-connectivity of the primary somatosensory cortex in Parkinson’s disease: a resting-state functional MRI study

  2024cites this paper
• State entropy reveals the reconfiguration of brain complexity in Parkinson’s disease

  2024cites this paper
• Predicting the occurrence of mild cognitive impairment in Parkinson’s disease using structural MRI data

  2024cites this paper
• Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [18F]FECNT-d4

  2024cites this paper
• Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson’s disease revealed by in vivo PET imaging

  2023cites this paper
• Adaptation strategies and neurophysiological response in early-stage Parkinson's disease: BioVRSea approach

  2023cites this paper
• Parkinson’s disease progression: Increasing expression of an invariant common core subnetwork

  2023cites this paper
• Targeting the microbiota-mitochondria crosstalk in neurodegeneration with senotherapeutics.

  2023cites this paper
• Accelerometer-Based Timing Analysis for Parkinson's Disease Classification

  2023cites this paper
• Large-scale activation likelihood estimation meta-analysis of parkinsonian disorders

  2023cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions

  2023cites this paper
• Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease

  2023cites this paper
• Visualizing alpha‐synuclein and iron deposition in M83 mouse model of Parkinson's disease in vivo

  2023cites this paper
• Lifestyle modulators of neuroplasticity in Parkinson's disease: evidence in human neuroimaging studies.

  2023cites this paper
• Primary motor area-related injury of anterior central gyrus in Parkinson's disease with dyskinesia: a study based on MRS and Q-Space.

  2023cites this paper
• Roles of molecular neuroimaging techniques in Parkinsonism

  2023cites this paper
• Machine learning application for classification of Alzheimer's disease stages using 18F-flortaucipir positron emission tomography

  2023cites this paper
• Structural and Molecular Imaging for Clinically Uncertain Parkinsonism

  2023cites this paper
• Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

  2023cites this paper
• Deep learning application for the classification of Alzheimer’s disease using 18F-flortaucipir (AV-1451) tau positron emission tomography

  2023cites this paper
• A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson’s disease

  2023cites this paper
• Graph-Based Analysis of Brain Connectivity in Multiple Sclerosis Using Functional MRI: A Systematic Review

  2023cites this paper
• Is disease a threat to identity? A systematic review of parkinson's disease and personal identity

  2023cites this paper
• Machine learning models for diagnosis and prognosis of Parkinson's disease using brain imaging: general overview, main challenges, and future directions

  2023cites this paper
• Depression as a Prodromal Symptom of Neurodegenerative Diseases.

  2023cites this paper
• Progressive supranuclear palsy: A case report and brief review of the literature

  2023cites this paper
• Abnormalities of cerebral blood flow and the regional brain function in Parkinson’s disease: a systematic review and multimodal neuroimaging meta-analysis

  2023cites this paper
• Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson’s Disease

  2022cites this paper
• Spatially-directed magnetic molecularly imprinted polymers with good anti-interference for simultaneous enrichment and detection of dual disease-related bio-indicators.

  2022cites this paper
• Brain proton magnetic resonance spectroscopy in patients with Parkinson’s disease

  2022cites this paper
• Multi-View Brain Network Analysis with Cross-View Missing Network Generation

  2022cites this paper
• Metabolic assessment of cerebral palsy with normal clinical MRI using 18F-FDG PET imaging: A preliminary report

  2022cites this paper
• Mapping microstructural gradients of the human striatum in normal aging and Parkinson’s disease

  2022cites this paper
• Predictors of RBD progression and conversion to synucleinopathies

  2022cites this paper
• Combined assessment by transcranial sonography and Sniffin' Sticks test has a similar diagnostic accuracy compared to brain SPECT for Parkinson's disease diagnosis.

  2022cites this paper
• Future Prospects in Parkinson's Disease Diagnosis and Treatment.

  2022cites this paper
• 60 Years of Achievements by KSNM in Neuroimaging Research

  2022cites this paper
• Doença de Parkinson secundária a COVID-19: uma revisão sistemática

  2022cites this paper
• HDAC Inhibitors: Innovative Strategies for Their Design and Applications

  2022cites this paper
• Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia

  2022cites this paper
• PET imaging in animal models of Parkinson's disease.

  2022cites this paper
• Nuclear imaging in Parkinson's disease: The past, the present, and the future.

  2022cites this paper
• Prionopathies and Prionlike Protein Aberrations in Neurodegenerative Diseases

  2021cites this paper
• Diagnosis of Parkinson Disease: Imaging and Non-Imaging Techniques

  2021cites this paper
• A multi-scanner neuroimaging data harmonization using RAVEL and ComBat

  2021cites this paper
• Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

  2021cites this paper
• Small P values may not yield robust findings: an example using REST-meta-PD.

  2021cites this paper
• Nervonic Acid Ameliorates Motor Disorder in Mice with Parkinson’s Disease

  2021cites this paper
• Identification of REM Sleep Behavior Disorder by Structural Magnetic Resonance Imaging and Machine Learning

  2021cites this paper
• A deep learning approach for classification and diagnosis of Parkinson’s disease

  2021cites this paper
• Nervonic acid amends motor disorder in a mouse model of Parkinson’s disease

  2021cites this paper
• Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease.

  2021cites this paper
• In-flow electrochemical detection of chemicals in droplets with pyrolysed photoresist electrodes: application as a module for quantification of microsampled dopamine.

  2021cites this paper
• Enantiomeric purity deviations of radiolabelled amino acids obtained from chiral columns

  2021cites this paper
• A Role of PET/MR Imaging in Dementia?

  2021cites this paper
• Novel targeted therapies for Parkinson’s disease

  2021cites this paper
• A Deep Learning Approach for Classi�cation and Diagnosis of Parkinson’s Disease

  2021cites this paper
• Identification of blood-based biomarkers for diagnosis and prognosis of Parkinson's disease: A Systematic review of proteomics studies.

  2021cites this paper
• The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity

  2021cites this paper
• Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.

  2021cites this paper
• Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease

  2021cites this paper
• A pilot study of magnetic resonance fingerprinting in Parkinson's disease

  2020cites this paper
• Diffusion Tensor Imaging-Based Studies at the Group-Level Applied to Animal Models of Neurodegenerative Diseases

  2020cites this paper
• Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson’s disease

  2020cites this paper
• Brain Functional and Structural Signatures in Parkinson’s Disease

  2020cites this paper
• PET imaging with [18F]FP-(+)-DTBZ in 6-OHDA-induced partial and full unilaterally-lesioned model rats of Parkinson's disease and the correlations to the biological data.

  2020cites this paper
• Striatal dopamine receptor 2 and 3 availability in alcohol dependence

  2020cites this paper
• Radiopharmaceutical Sciences

  2020cites this paper
• Parkinson’s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

  2020cites this paper